Drug Profile
SPC 4955
Alternative Names: SPC-4955Latest Information Update: 22 Mar 2016
Price :
$50
*
At a glance
- Originator Santaris Pharma
- Developer Roche
- Class Antihyperlipidaemics; Antisense oligonucleotides
- Mechanism of Action Apolipoprotein B-100 expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia
Most Recent Events
- 21 Nov 2011 Santaris Pharma completes a Phase-I trial in healthy volunteers in Germany (NCT01365663)
- 11 May 2011 Phase-I clinical trials in Hypercholesterolaemia (in volunteers) in Germany (SC)
- 31 Dec 2007 Preclinical trials in Hypercholesterolaemia in Denmark (parenteral)